tozorakimab

AstraZeneca execs 'not worried' after IL-33 drug fails to improve COPD breathing in phase 2
Fierce Biotech
Sun, 09/8/24 - 11:35 pm
AstraZeneca
tozorakimab
COPD
clinical trials